vs
Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and Sila Realty Trust, Inc. (SILA). Click either name above to swap in a different company.
Sila Realty Trust, Inc. is the larger business by last-quarter revenue ($50.1M vs $47.7M, roughly 1.0× IRONWOOD PHARMACEUTICALS INC). Sila Realty Trust, Inc. runs the higher net margin — 10.0% vs -4.8%, a 14.8% gap on every dollar of revenue. On growth, Sila Realty Trust, Inc. posted the faster year-over-year revenue change (7.6% vs -47.3%). Over the past eight quarters, Sila Realty Trust, Inc.'s revenue compounded faster (-0.6% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
Sila Realty Trust, Inc. is a U.S.-based real estate investment trust that owns, operates, and acquires high-quality income-generating commercial properties. Its core portfolio covers industrial logistics facilities, office assets and mixed-use properties, serving tenants across logistics, corporate and retail segments to deliver stable long-term returns.
IRWD vs SILA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.7M | $50.1M |
| Net Profit | $-2.3M | $5.0M |
| Gross Margin | — | 88.9% |
| Operating Margin | 14.3% | — |
| Net Margin | -4.8% | 10.0% |
| Revenue YoY | -47.3% | 7.6% |
| Net Profit YoY | -200.9% | -54.9% |
| EPS (diluted) | $0.01 | $0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.7M | $50.1M | ||
| Q3 25 | $122.1M | $49.8M | ||
| Q2 25 | $85.2M | $48.7M | ||
| Q1 25 | $41.1M | $48.3M | ||
| Q4 24 | $90.5M | $46.5M | ||
| Q3 24 | $91.6M | $46.1M | ||
| Q2 24 | $94.4M | $43.6M | ||
| Q1 24 | $74.9M | $50.6M |
| Q4 25 | $-2.3M | $5.0M | ||
| Q3 25 | $40.1M | $11.6M | ||
| Q2 25 | $23.6M | $8.6M | ||
| Q1 25 | $-37.4M | $7.9M | ||
| Q4 24 | $2.3M | $11.1M | ||
| Q3 24 | $3.6M | $11.9M | ||
| Q2 24 | $-860.0K | $4.6M | ||
| Q1 24 | $-4.2M | $15.0M |
| Q4 25 | — | 88.9% | ||
| Q3 25 | — | 88.1% | ||
| Q2 25 | — | 87.7% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 87.3% | ||
| Q3 24 | — | 87.4% | ||
| Q2 24 | — | 86.6% | ||
| Q1 24 | — | 89.0% |
| Q4 25 | 14.3% | — | ||
| Q3 25 | 61.8% | — | ||
| Q2 25 | 53.2% | — | ||
| Q1 25 | -70.7% | — | ||
| Q4 24 | 34.8% | — | ||
| Q3 24 | 28.0% | — | ||
| Q2 24 | 26.5% | — | ||
| Q1 24 | 14.7% | — |
| Q4 25 | -4.8% | 10.0% | ||
| Q3 25 | 32.8% | 23.3% | ||
| Q2 25 | 27.7% | 17.6% | ||
| Q1 25 | -90.9% | 16.4% | ||
| Q4 24 | 2.5% | 23.9% | ||
| Q3 24 | 4.0% | 25.9% | ||
| Q2 24 | -0.9% | 10.6% | ||
| Q1 24 | -5.6% | 29.6% |
| Q4 25 | $0.01 | $0.10 | ||
| Q3 25 | $0.23 | $0.21 | ||
| Q2 25 | $0.14 | $0.15 | ||
| Q1 25 | $-0.23 | $0.14 | ||
| Q4 24 | $0.03 | $0.20 | ||
| Q3 24 | $0.02 | $0.21 | ||
| Q2 24 | $-0.01 | $0.08 | ||
| Q1 24 | $-0.03 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $215.5M | $32.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-261.8M | $1.3B |
| Total Assets | $396.9M | $2.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $215.5M | $32.3M | ||
| Q3 25 | $140.4M | $27.7M | ||
| Q2 25 | $92.9M | $24.8M | ||
| Q1 25 | $108.5M | $30.5M | ||
| Q4 24 | $88.6M | $39.8M | ||
| Q3 24 | $88.2M | $28.6M | ||
| Q2 24 | $105.5M | $87.0M | ||
| Q1 24 | $121.5M | $90.2M |
| Q4 25 | — | — | ||
| Q3 25 | $199.5M | — | ||
| Q2 25 | $199.3M | — | ||
| Q1 25 | $199.2M | — | ||
| Q4 24 | $199.0M | — | ||
| Q3 24 | $198.8M | — | ||
| Q2 24 | $198.6M | — | ||
| Q1 24 | $398.3M | — |
| Q4 25 | $-261.8M | $1.3B | ||
| Q3 25 | $-264.2M | $1.3B | ||
| Q2 25 | $-308.2M | $1.4B | ||
| Q1 25 | $-334.1M | $1.4B | ||
| Q4 24 | $-301.3M | $1.4B | ||
| Q3 24 | $-311.3M | $1.4B | ||
| Q2 24 | $-321.7M | $1.5B | ||
| Q1 24 | $-330.5M | $1.5B |
| Q4 25 | $396.9M | $2.1B | ||
| Q3 25 | $396.1M | $2.1B | ||
| Q2 25 | $342.9M | $2.0B | ||
| Q1 25 | $327.2M | $2.0B | ||
| Q4 24 | $350.9M | $2.0B | ||
| Q3 24 | $389.5M | $2.0B | ||
| Q2 24 | $395.6M | $2.1B | ||
| Q1 24 | $438.8M | $2.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $74.6M | $119.1M |
| Free Cash FlowOCF − Capex | $74.6M | — |
| FCF MarginFCF / Revenue | 156.3% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 23.76× |
| TTM Free Cash FlowTrailing 4 quarters | $127.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $119.1M | ||
| Q3 25 | $47.6M | $30.0M | ||
| Q2 25 | $-15.1M | $31.9M | ||
| Q1 25 | $20.0M | $24.1M | ||
| Q4 24 | $15.2M | $132.8M | ||
| Q3 24 | $9.9M | $29.1M | ||
| Q2 24 | $33.5M | $31.6M | ||
| Q1 24 | $45.0M | $36.6M |
| Q4 25 | $74.6M | — | ||
| Q3 25 | $47.6M | — | ||
| Q2 25 | $-15.1M | — | ||
| Q1 25 | $19.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.9M | — | ||
| Q2 24 | $33.4M | — | ||
| Q1 24 | $44.9M | — |
| Q4 25 | 156.3% | — | ||
| Q3 25 | 39.0% | — | ||
| Q2 25 | -17.7% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 35.4% | — | ||
| Q1 24 | 60.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 23.76× | ||
| Q3 25 | 1.19× | 2.59× | ||
| Q2 25 | -0.64× | 3.71× | ||
| Q1 25 | — | 3.06× | ||
| Q4 24 | 6.74× | 11.95× | ||
| Q3 24 | 2.71× | 2.43× | ||
| Q2 24 | — | 6.84× | ||
| Q1 24 | — | 2.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
